Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accounts Payables (2019 - 2025)

Eton Pharmaceuticals' Accounts Payables history spans 7 years, with the latest figure at $14.3 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 431.26% year-over-year to $14.3 million; the TTM value through Sep 2025 reached $14.3 million, up 431.26%, while the annual FY2024 figure was $4.2 million, 125.49% up from the prior year.
  • Accounts Payables for Q3 2025 was $14.3 million at Eton Pharmaceuticals, up from $12.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $14.3 million in Q3 2025 and bottomed at $1.1 million in Q3 2022.
  • The 5-year median for Accounts Payables is $2.1 million (2022), against an average of $3.4 million.
  • The largest annual shift saw Accounts Payables tumbled 67.8% in 2022 before it surged 469.25% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $1.8 million in 2021, then decreased by 0.45% to $1.8 million in 2022, then increased by 4.64% to $1.8 million in 2023, then skyrocketed by 125.49% to $4.2 million in 2024, then soared by 242.19% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Accounts Payables are $14.3 million (Q3 2025), $12.1 million (Q2 2025), and $4.9 million (Q1 2025).